Physician profile
Timothy Horner
NPI 1336246800
$1,359.24
in general payments reported to CMS, 2019-2025
17 companies · $14.73 in 2025
The $14.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $155 · 2021: $86.76 · 2022: $66.65 · 2025: $14.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $248.27 | 2019-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $197.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $190.64 | 2019-2021 | |
| Novo Nordisk INC | $131.29 | 2019-2020 | |
| Pfizer INC. | $124.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $78.97 | 2019 | |
| Amgen INC. | $73.92 | 2019-2021 | |
| Allergan, INC. | $71.50 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $66.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.04 | 2019-2021 | |
| Corcept Therapeutics | $35.65 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.97 | 2019 | |
| Astellas Pharma US INC | $19.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.25 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.